We calculated the TF activity for these samples based on the LINGER-inferred cell population GRN from PBMCs and found that FOXN1 is significantly less active in patients with AML than in healthy donors, and it is not differentially expressed (Fig. 6a,b). This evidence concerns the gene FOXN1 and acute myeloid leukemia.